In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome

Menée notamment sur des modèles murins de lymphome, cette étude met en évidence la possibilité de générer in vivo, à l'aide de vecteurs lentiviraux, des lymphocytes CAR-T ciblant l'antigène CD19, puis montre que cette stratégie induit une réduction du nombre de lymphocytes B et des signes histopathologiques de syndrome de libération de cytokines

Résumé en anglais

Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B-cell malignancies. Notwithstanding, CAR T-cell manufacturing requires complex procedures impeding the broad supply chain. Here, we provide evidence that human CD19-CAR T cells can be generated directly in vivo using the lentiviral vector CD8-LV specifically targeting human CD8+ cells. Administration into mice xenografted with Raji lymphoma cells and human peripheral blood mononuclear cells led to CAR expression solely in CD8+ T cells and efficacious elimination of CD19+ B cells. Further, upon injection of CD8-LV into mice transplanted with human CD34+ cells, induction of CAR T cells and CD19+ B-cell depletion was observed in 7 out of 10 treated animals. Notably, three mice showed elevated levels of human cytokines in plasma. Tissue-invading CAR T cells and complete elimination of the B-lymphocyte-rich zones in spleen were indicative of a cytokine release syndrome. Our data demonstrate the feasibility of in vivo reprogramming of human CD8+ CAR T cells active against CD19+ cells, yet with similar adverse effects currently notorious in the clinical practice.